Home>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> PI3K>>AZD8835

AZD8835 Sale

目录号 : GC11248

An inhibitor of PI3Kα and PI3Kδ

AZD8835 Chemical Structure

Cas No.:1620576-64-8

规格 价格 库存 购买数量
1mg
¥504.00
现货
5mg
¥1,582.00
现货
10mg
¥2,912.00
现货
25mg
¥6,062.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

IC50: 6.2 and 5.7 nM for PI3Kα and PI3Kδ, respectively

AZD8835 is a dual PI3Kα and PI3Kδ inhibitor.

The PIK3CA gene, encoding the p110α catalytic unit of PI3Kα, is one of the most mutated oncogenes in human cancer. Therefore, PI3Kα is a critical target in identifying inhibitors and testing their therapeutic application.

In vitro: AZD8835 was identified as a potent dual inhibitor of PI3Kα and PI3Kδ with good selectivity versus PI3Kβ, PI3Kγ, as well as other kinases that readily inhibited cell growth with mutant PIK3CA status, such as in estrogen receptor-positive breast cancer cell lines including MCF7, BT474, and T47D [1].

In vivo: Previous animal study demonstrated that AZD8835 had antitumor efficacy in breast cancer xenograft models when AZD8835 was continuously dosed. In addition, the monotherapy of AZD8835 was found to be able to induce tumor xenograft regression by using Intermittent High-Dose Scheduling (IHDS). Furthermore, AZD8835 IHDS treatment in combination with other targeted therapeutic agents could further enhance its antitumor activity by up to 92% regression [1].

Clinical trial: A phase I, dose study has been conducted to evaluate the safety and PK of AZD8835 in patients with advanced solid tumours, and this study is still ongoing [https://clinicaltrials.gov/ct2/show/NCT02260661term=AZD8835&rank=1].

Reference:
[1] Hudson K et al.  Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers. Mol Cancer Ther.2016 May;15(5):877-89.

Chemical Properties

Cas No. 1620576-64-8 SDF
化学名 1-(4-(5-(5-amino-6-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one
Canonical SMILES O=C(N1CCC(C2=NN(CC)C(C3=NC(C4=NN=C(C(C)(C)C)O4)=C(N)N=C3)=N2)CC1)CCO
分子式 C22H31N9O3 分子量 469.54
溶解度 DMF: 16 mg/ml,DMSO: 16 mg/ml,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml,Ethanol: 2 mg/ml 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.1297 mL 10.6487 mL 21.2974 mL
5 mM 0.4259 mL 2.1297 mL 4.2595 mL
10 mM 0.213 mL 1.0649 mL 2.1297 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置